To estimate associations between use of ␤-blockers, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers (ARBs) and breast cancer recurrence in a large Danish cohort.
INTRODUCTION
␤-Blockers competitively inhibit the binding of norepinephrine and epinephrine to ␤-adrenergic receptors, interrupting downstream signaling. 1 The stress hormone norepinephrine may affect the progression of various cancers, and laboratory models show that the ␤-blocker propranolol inhibits norepinephrine-induced breast cancer migration to metastatic sites. [2] [3] [4] [5] [6] Recent epidemiologic studies suggest that ␤-blockers prevent breast cancer progression. [7] [8] [9] [10] [11] [12] Some studies have associated ␤-blockers with reduced recurrence risk or improved survival in patients with breast cancer, and this association may depend on the receptor selectivity of the drug.
7-10 Another study showed no association between ␤-blockers and breast cancer survival. 13 Several studies suggest that angiotensinconverting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) also have anticancer properties, 14 whereas others report increased cancer risk 15 or no association. [16] [17] [18] [19] Two studies have specifically addressed breast cancer outcomes among users of ACEi and ARBs. One showed a decreased recurrence risk in users of ARBs or ACEi. 20 The other showed no association for patients taking both ACEi and ␤-blockers, but an increased recurrence risk in exclusive ACEi users.
To address conflicting evidence from earlier studies, we estimated associations between use of ␤-blockers, ACEi, and ARBs and the breast cancer recurrence rate in a large cohort of Danish breast cancer survivors.
PATIENTS AND METHODS

Source Population and Data Collection
We conducted a nationwide cohort study using the population-based medical and prescription registries of Denmark, which cover all of the country's ϳ5.6 million inhabitants. A unique civil personal registration number is assigned to all Danish residents, allowing individual-level linkage of registries. 21 The Danish Breast Cancer Cooperative Group (DBCG) registry has prospectively enrolled nearly all Danish patients with breast cancer since 1977.
22,23 DBCG enrollees undergo follow-up examinations every 3 to 6 months for the first 5 years after diagnosis and then annually for years 6 to 10. 23 Recurrences diagnosed between examinations are also reported to the registry. From this registry we identified all women diagnosed with an incident invasive breast cancer (Union for International Cancer Control stage I to III) between 1996 and 2003 who were placed on a standard DBCG treatment protocol. We ascertained age and menopausal status at diagnosis, type of primary therapy, Union for International Cancer Control stage, histologic grade, tumor estrogen receptor (ER) status, receipt of adjuvant chemotherapy, radiotherapy, and endocrine therapy (ET), date and anatomic site of recurrence, and date of death or emigration.
The Danish National Prescription Registry has automatically recorded all prescriptions dispensed at Danish pharmacies since 1995. For each prescription the database records the date, patient's civil personal registration number, drug prescribed (using the Anatomic Therapeutic Chemical classification system), and fill quantity. 24 We linked the breast cancer cohort to this registry to ascertain exposure to ␤-blockers, ACEi, and ARBs (Appendix Table  A1 , online only). We also characterized exposure to potentially confounding comedications previously associated with breast cancer outcomes (ie, simvastatin, 25 aspirin, 26 and prediagnosis combination hormone replacement therapy 27 ) and to other drugs (Appendix Table A2 , online only). We used the Danish National Registry of Patients to summarize each patient's medical history from 1977 until her breast cancer diagnosis. 28 We searched the registry for diagnoses that comprise the Charlson comorbidity index, 29 excluding breast cancer (Appendix Table A3 , online only). We also ascertained history of diagnosed obesity, arrhythmia, angina pectoris, esophageal varices, tremor, thyrotoxicosis, migraine, chronic obstructive pulmonary disease, and asthma (Appendix Table A4 , online only).
Definitions of Analytic Variables
Age at diagnosis was categorized by decade in stratified analyses, but modeled continuously in multivariate models. Person-time at risk for recurrence was defined as the number of days elapsed between the date of primary surgery and the first of breast cancer recurrence, death, emigration, or December 31, 2010. Breast cancer recurrence is defined by DBCG protocol as any local, regional, or distant recurrence or cancer of the contralateral breast. 23 We estimated site-specific recurrence associations for the following anatomic sites: bone, lymph nodes, ipsilateral breast, contralateral breast, lung, liver, or CNS. We also defined a distant recurrence outcome in which women with ipsilateral recurrence or contralateral recurrence were censored on their event dates. Histologic grade was classified as low, moderate, or high. Receipt of adjuvant chemotherapy and radiotherapy were defined dichotomously. ER status and receipt of ET were summarized into a joint variable (ERϩ/ETϩ, ER-/ET-, ERϩ/ET-). Patients with ER-negative tumors who received ET contrary to indication (ER-/ETϩ, n ϭ 36) were excluded from the cohort. Because this group accounted for a miniscule proportion of patients, we deemed exclusion to be the most appropriate technique by which to account for their anomalous treatment profile. Results from analyses including this subgroup did not differ from the analyses reported herein.
Time-dependent drug exposures were updated yearly over follow-up. Positive exposure in each year was defined as having at least one prescription during that year for the drug class of interest. Exposures to ␤-blockers, ACEi, and ARBs were defined in several ways. In the simplest case, we defined ever/never exposure to each drug class. These drugs are available as combination tablets containing either calcium channel blockers or diuretics, so we also defined pure exposure to each class (ie, noncombination tablets only). ␤-Blockers with ␣-adrenergic effects were excluded from the pure ␤-blocker group. ␤-Blocker exposures were also defined by receptor selectivity (nonselective or ␤1-selective) and by lipid solubility (highly, moderately, or weakly lipophilic). ␤-Blocker and ARB exposures were also defined by specific drugs. We made our exposure definitions exclusive to avoid misclassification from class switching. For example, nonselective ␤-blocker exposure was positive if 100% of a woman's ␤-blocker prescriptions were for nonselective drugs. We calculated duration of exposure as the cumulative number of years exposed since 1995. Duration was categorized as 0 (no exposure history), 1 to 5, 6 to 10, and more than 10 cumulative years of exposure.
To evaluate the effect of prediagnosis exposure, we conducted a subanalysis in the subset of women with Ն 3 years of prescription data before their breast cancer diagnosis (n ϭ 14,424). We defined prediagnostic exposure in categories of total tablets prescribed in the 3 years preceding breast cancer diagnosis (1 to 100, 101 to 1,000 and Ն 1,001 tablets). We accounted for drug discontinuation by modeling the gap (in days) between completing the last prescription and the diagnosis date. Duration of the last prescription was estimated as the product of the fill quantity and the tablet strength, divided by the defined daily dose associated with the Anatomic Therapeutic Chemical code.
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Statistical Analysis
We tabulated the frequency and proportion of ever-users and neverusers of ␤-blockers, ACEi, and ARBs within categories of covariates (Table 1) .
We estimated 10-year recurrence associations using Cox regression models. Time-varying drug exposures were lagged by 1 year to allow a reasonable induction period for an effect on recurrence and to guard against the possibility that subclinical recurrences affected prescribing or adherence. Drug exposure durations were modeled as time-varying covariates in separate analyses. Multivariate models featured mutual adjustment for ␤-blockers, ACEi, and ARBs as well as for prognostic factors, Charlson comorbidity index, 29 and potentially confounding coprescriptions. Proportionality of hazard functions was checked by evaluating Wald tests of cross-product terms between main exposures and the logarithm of person-time. 31 To evaluate potential residual confounding by a secondary list of comorbidities and comedications while managing model dimensionality, we calculated a recurrence risk score from the logistic regression of recurrence on dichotomously defined prediagnosis exposure to the medications listed in Appendix Table A2 and prediagnosis history of the conditions listed in Appendix Table A4 . Coefficients from this model were adjusted for use of ␤-blockers, ACEi, and ARBs and were used to calculate each patient's probability of recurrence as a function of their observed exposure to the additional drugs and diagnoses. The continuous probability was categorized into deciles and modeled with design variables in multivariate proportional hazards models as described previously. Hazard ratios for main exposures were compared between multivariate models with and without the risk score to judge whether the risk score encoded substantial confounding.
We evaluated effect measure modification by ER status, histologic grade, and menopausal status in stratified multivariate models. Heterogeneity of associations by recurrence site was explored using competing risks proportional hazards models.
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In the subcohort of women with at least 3 years of prediagnosis prescription data, we simultaneously modeled categories of the number of tablets prescribed in the 3-year period before diagnosis, longitudinal postdiagnosis exposures (as previously), and the gap between last prediagnosis exposure and diagnosis (continuous).
All analyses were performed with SAS v.9.2 (SAS Institute, Cary, NC). The study was approved by the DBCG and the Danish Data Protection Agency (record no. 2010-41-4979). Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BCS, breast-conserving surgery; COPD, chronic obstructive pulmonary disease; E, estrogen; ER, estrogen receptor; ET, adjuvant endocrine therapy; ICD, International Classification of Diseases; HRT, hormone replacement therapy; NSAIDs, nonsteroidal anti-inflammatory drugs; P, progesterone; RT, radiotherapy; UICC, Union for International Cancer Control.
‫ء‬
The conditions were defined as in the Carlson Comorbidity index (see Appendix Table A3 , online only, for ICD codes). †The conditions were defined by combining ICD codes for the diseases (see Appendix Table A4 , online only) and the history of any redeemed prescription for the condition (defined by Anatomical Therapeutic Chemical codes listed in Appendix Table A2 , online only). Hypertension was not included as a variable because most people in Denmark are treated for hypertension by their primary care provider so the number of patients with a hospital admission code for hypertension would underestimate the true prevalence. For the same reason we also did not include hospital admission codes for stress/anxiety or depression, because most people in Denmark with these conditions will be treated by their primary care provider or at outpatient clinics at psychiatric hospitals.
RESULTS
We enrolled 18,733 women diagnosed with invasive breast cancer between 1996 and 2003 ( Table 1) . There were 3,414 recurrences over 113,799 person-years of follow-up (median ϭ 6.8 years). There were 3,660 users of ␤-blockers, 3,075 users of ACEi, and 1,989 users of ARBs. The median total number of tablets prescribed to patients with one to five, six to 10, and more than 10 years of cumulative exposure were 400, 2,541, and 3,770, respectively, for any ␤-blocker; 330, 2,530, and 3,730, respectively, for any ACEi; and 588, 2,282, and 3,717, respectively, for any ARB. Median cumulative duration of exposure under our various definitions is reported in Table 2 . Table 1 shows the distribution of prognostic factors, comorbidities, and comedications among never and ever users of ␤-blockers, ACEi, and ARBs. Users of these drugs were older (median age, 62 to 63 years for users v 56 to 57 for nonusers), more likely to be postmenopausal at diagnosis (83% to 87% of users v 67% to 68% of nonusers), and less likely to receive adjuvant chemotherapy (17% to 19% of users v 30% to 32% of nonusers). Users generally had more coprescriptions and comorbidities than nonusers.
Results from multivariate models were similar with and without adjustment for the recurrence risk score, and conclusions did not differ between models using cumulative exposure duration and those using lagged exposure status. We therefore present associations estimated with lagged exposure models that were not adjusted for the risk score.
␤-Blockers and Breast Cancer Recurrence
Most ␤-blocker prescriptions were for ␤1-selective drugs (71%). Only 3.4% of prescriptions were for combination tablets. Twenty-two percent of ␤-blocker prescriptions were for highly lipophilic drugs, 56% were for moderately lipophilic drugs, and 22% were for weakly lipophilic drugs. The most prevalent individual drugs were metoprolol (49% of all ␤-blocker prescriptions), atenolol (17%), and propranolol (16%) (Appendix Table A1 ).
During a maximum of 10 years of follow-up, there were 466 recurrences among ␤-blocker users (Table 2) . Compared with never users, users of any ␤-blocker had a slightly lower recurrence hazard in unadjusted models (unadjusted hazard ratio [HR] ϭ 0.91; 95% CI, 0.81 to 1.0) and a slightly higher recurrence hazard in adjusted models (adjusted HR ϭ 1.3; 95% CI, 1.1 to 1.5). Exposure definitions were specified a priori to isolate exposure by purity (noncombination tablets), receptor selectivity, and lipid solubility. Crude and adjusted models under these definitions showed either null-centered or slightly 
‫ء‬
All prescription exposure characterizations were updated yearly over follow-up and coded as time-varying variables. All prescription exposures were lagged by 1 year. Subexposures were made exclusive (eg, for noncombination ␤-blockers, exposure was considered positive only if 100% of a woman's ␤-blocker prescriptions were for noncombination drugs).
†Adjusted for age at diagnosis (continuous), menopausal status at diagnosis, UICC stage (design variables), histologic grade (design variables), ER status and receipt of adjuvant endocrine therapy (conjugated, design variables), receipt of adjuvant chemotherapy, type of primary surgery received, Charlson comorbidity index (design variables), prediagnosis combination HRT, and coprescriptions (time-varying, updated yearly, and lagged by 1 year) of any ␤-blockers, ACE inhibitors, ARBs, aspirin, and simvastatin. (Table 2 ). The pattern of associations across solubility categories suggested a dominant association for one of the component drugs in the moderately lipophilic category, which motivated estimation of associations for individual drugs. Exclusive use of metoprolol and sotalol were positively associated with recurrence, whereas the remaining drugs seemed to have null associations (metoprolol: adjusted HR ϭ 1.5, 95% CI, 1.2 to 1.8; sotalol: adjusted HR ϭ 2.0, 95% CI, 0.99 to 4.0).
Single addition of covariates showed that three variables had the largest impact on the progression from somewhat protective unadjusted associations to somewhat positive adjusted associations between ␤-blockers and recurrence. These were use of simvastatin (15.6% increase in the estimate), use of ARBs (10.8% increase in the estimate), and histologic grade (9.9% increase in the estimate).
ACEi, ARBs, and Breast Cancer Recurrence
Enalapril (47%) and ramipril (17%) accounted for most of the ACEi prescriptions, and 12% of prescriptions were for combination tablets. The most prevalent ARBs were losartan (50%), candesartan (22%), and valsartan (11%). Approximately one third of all ARB prescriptions were for combination tablets (Appendix Table A1 ).
There were 329 and 218 breast cancer recurrences among users of ACEi and ARBs, respectively, over a maximum of 10 years of followup. We observed near-null associations between use of any ACEi or any ARB and breast cancer recurrence, compared with never users (ACEi: adjusted HR ϭ 1.2, 95% CI, 0.97 to 1.4; ARBs: adjusted HR ϭ 1.1, 95% CI, 0.85 to 1.3). The null associations persisted for exposure to noncombination ACEi and ARB tablets (Table 2 ) and for individual ARB tablets (data not shown).
19 Table 3 reports associations stratified by ER status, histologic grade, and menopausal status. We did not observe modification by these variables of the HRs for overall exposure to ␤-blockers, ACEi, and ARBs. We found that exclusive use of metoprolol was associated with an increased recurrence risk only in ER-positive patients (for ER-positive: adjusted HR ϭ 1.5, 95% CI, 1.2 to 1.9; for ER-negative: adjusted HR ϭ 1.0, 95% CI, 0.61 to 1.8). The metoprolol association was also stronger in the premenopausal stratum than in the postmenopausal stratum (premenopausal HR ϭ 2.6, 95% CI, 1.6 to 4.4; postmenopausal HR ϭ 1.3, 95% CI, 1.0 to 1.6).
For all exposures, associations with specific sites of recurrence and with distant recurrence did not differ substantially from the broader outcome of any recurrence (data not shown). We also conducted our analyses in the subset of the cohort without another malignancy diagnosed before breast cancer (n ϭ 18,213), with essentially identical results (data not shown).
In the restricted cohort (n ϭ 14,424) evaluating intensity and timing of drug exposures in the 3 years preceding breast cancer diagnosis, we found no pattern of association. Recurrence associations for lagged postdiagnosis drug exposures moved nearer to the null when modeled simultaneously with prediagnosis exposure (Appendix Table  A5 , online only).
DISCUSSION
In this large, prospective cohort study, we found no evidence for a protective effect of ␤-blockers, ACEi, or ARBs on breast cancer recurrence. Null associations were apparent under most drug exposure definitions, including those isolating tablet purity, selectivity and solubility of ␤-blockers, and individual ␤-blocker and ARB drugs. Some definitions of ␤-blocker exposure were associated with an increased recurrence rate, and these seem to have been driven by positive associations with metoprolol and sotalol. These may reflect chance findings arising from small subgroups. Exploration of pre-and postdiagnostic exposure timing and intensity continued to show null associations.
The main strengths of our study are its large size and use of high-quality, prospectively collected exposure and outcome data from independent registries. The population-based design within the setting of a tax-supported universal health care system greatly reduces the threat of selection bias. The DBCG registry provides detailed information on prognostic factors, and each patient is followed closely for recurrence after breast cancer diagnosis, yielding data quality and completeness of follow-up similar to that of most clinical trials.
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In our main analysis, the associations between ␤-blocker use and recurrence shifted from protective-to-null in unadjusted models to null-to-positive in multivariate models. Three covariates-use of simvastatin, use of ARBs, and histologic grade-accounted for the majority of that shift.
Several limitations qualify the interpretation of our findings. Body mass index (BMI) data were not available and could potentially confound our results. However, a previous study that overlapped with our source population showed BMI to be positively associated only with distant recurrences. 33 The null-centered recurrence associations we observed across specific anatomic sites argue against the attenuation of truly protective associations by positive confounding from BMI. We used prescriptions logged in a registry to stand proxy for actual use of the drugs we studied, potentially leading to misclassification of exposures. However, only filled prescriptions are logged in the registry, and because patients had to pay a portion of the drug cost, it is likely that dispensed medications were received by patients who complied with the prescription. In support of this expectation, a validation study of hormone replacement therapy use among Danish nurses showed strong agreement between self-reported use and use ascertained from the registry. 34 It is also important to note that prediagnosis drug exposure data were left truncated because the prescription registry start date. Cumulative exposure duration was thus misclassified, and our categories define only the lower limits of true duration. Prediagnosis exposure intensity was defined as the cumulative number of tablets prescribed; intensity may therefore be underestimated for women taking extended-release drug formulations.
In contrast with our null-centered results, some earlier studies suggested a protective effect of ␤-blockers on breast cancer recurrence or mortality, but each had important limitations. Powe et al 7 were first to suggest a protective role of ␤-blockers on survival and recurrence in patients with breast cancer. Their study included 43 ␤-blocker-exposed breast cancer survivors, most of whom (74%) were treated with ␤1-selective drugs. The Barron study compared women taking propranolol or atenolol during the year before breast cancer diagnosis with matched nonusers; cancer-specific mortality was lower among users of the nonselective agent propranolol (n ϭ 70; HR ϭ 0.19; 95% CI, 0.06 to 0.60), whereas there was no association among users of the ␤1-selective agent atenolol (n ϭ 525; HR ϭ 1.08; 95% CI, 0.84 to 1.61).
9 The Melhem-Bertrandt study found that 102 patients taking ␤-blockers (of whom 89% were prescribed a ␤1-selective agent) during neoadjuvant chemotherapy had longer relapse-free survival 
‫ء‬
All prescription exposure characterizations were updated yearly over follow-up and coded as time-varying variables. All prescription exposures were lagged by 1 year. Only exclusive users of the individual ␤-blockers were included. †Number of recurrences. ‡Comparing users with patients never prescribed the same drug class. Adjusted for age at diagnosis (continuous), menopausal status at diagnosis, UICC stage (design variables), histologic grade (design variables), ER status and receipt of adjuvant endocrine therapy (conjugated, design variables), receipt of adjuvant chemotherapy, type of primary surgery received, Charlson comorbidity index (design variables), prediagnosis combination HRT, and coprescriptions (time-varying, updated yearly, and lagged by 1 year) of any ␤-blockers, ACE inhibitors, ARBs, aspirin, and simvastatin. Stratification variables were removed from models when appropriate.
␤-Blockers, ACEi, ARBs, and Risk of Breast Cancer Recurrence www.jco.org compared with nonusers (HR ϭ 0.52; 95% CI, 0.31 to 0.88), conflicting with the results of the Barron study. 8 In the Ganz study, 204 patients taking ␤-blockers (the majority of whom were prescribed a ␤1-selective agent) during the year before or after breast cancer diagnosis had a slightly lower risk of recurrence and breast cancer-specific mortality (HR ϭ 0.86, 95% CI, 0.57 to 1.32; and HR ϭ 0.76, 95% CI, 0.44 to 1.33, respectively). 10 Our results agree with another recent study, which showed no association between ␤-blocker use and survival in 984 patients with breast cancer.
13
Only two previous population-based studies have been published on the associations between ACEi and ARBs and breast cancer outcomes, and their results are discordant. One study reported an increased risk of recurrence in patients taking ACEi during the year before or after breast cancer diagnosis (n ϭ 137; HR ϭ 1.56; 95% CI, 1.02 to 2.39).
10 Another study reported a decreased risk in patients treated with ACEi or ARBs, either contemporaneously with or after a breast cancer diagnosis (n ϭ 168; HR ϭ 0.60; 95% CI, 0.37 to 0.96).
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In summary, we saw no evidence of a protective effect of ␤-blockers, ACEi, or ARBs on breast cancer recurrence in a nationwide prospective cohort of Danish breast cancer survivors.
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‫ء‬
Other than ␤-blockers. †Other than ␤-blockers and calcium cannel blockers. 
